Placebo News and Research

RSS
Pilot study opens the door to a promising new therapeutic alternative for PTSD patients

Pilot study opens the door to a promising new therapeutic alternative for PTSD patients

Combination treatment could benefit smokers who also drink heavily

Combination treatment could benefit smokers who also drink heavily

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Clinical trial report endorses nitazoxanide as a safe drug for moderately ill COVID-19 patients

Clinical trial report endorses nitazoxanide as a safe drug for moderately ill COVID-19 patients

Nicotinamide riboside supplement shows promise as a potential therapy for Parkinson’s disease

Nicotinamide riboside supplement shows promise as a potential therapy for Parkinson’s disease

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

Researchers launch a multi-center trial to investigate new treatment for pediatric type 1 diabetes

Researchers launch a multi-center trial to investigate new treatment for pediatric type 1 diabetes

U of U Health researchers lead a $22-million nationwide clinical trial for rare brain disorder

U of U Health researchers lead a $22-million nationwide clinical trial for rare brain disorder

First platform trial for ALS hopes to accelerate the development of effective treatments

First platform trial for ALS hopes to accelerate the development of effective treatments

Antibiotics provide no benefit in preventing recurrent wheezing in infants hospitalized with RSV

Antibiotics provide no benefit in preventing recurrent wheezing in infants hospitalized with RSV

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Phase I clinical trial evaluates AI-discovered first anti-fibrotic small molecule inhibitor

Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses

Why pregnant people were left behind while vaccines moved at ‘warp speed’ to help the masses

Study reveals the various ways patients with multiple sclerosis acquire disability

Study reveals the various ways patients with multiple sclerosis acquire disability

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

New combination treatment strategy for managing metastatic hormone-sensitive prostate cancer

White blood cell count as a prognostic indicator of COVID-19

White blood cell count as a prognostic indicator of COVID-19

Outcomes of phase 3 clinical trial of CVO PLUS CURATIF capsules for COVID-19 treatment

Outcomes of phase 3 clinical trial of CVO PLUS CURATIF capsules for COVID-19 treatment

Generic version of Viagra could be the long-waited remedy for dogs with megaesophagus

Generic version of Viagra could be the long-waited remedy for dogs with megaesophagus

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

Combination of three drugs extends the survival of patients with metastatic, hormone-sensitive prostate cancer

New combination of antiviral drugs fails to improve outcomes in hospitalized patients with influenza

New combination of antiviral drugs fails to improve outcomes in hospitalized patients with influenza

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.